Lehrstuhl für Biochemie
Refine
Has Fulltext
- yes (121)
Is part of the Bibliography
- yes (121)
Year of publication
Document Type
- Doctoral Thesis (61)
- Journal article (57)
- Preprint (2)
- Book article / Book chapter (1)
Keywords
- Vaccinia-Virus (11)
- Maus (8)
- Replikation (8)
- cancer (8)
- oncolytic virotherapy (6)
- Proteine (5)
- SMN (5)
- identification (5)
- oncolytic virus (5)
- vaccinia virus (5)
- Cancer (4)
- DNA-Replikation (4)
- Small nuclear RNP (4)
- Vaccinia virus (4)
- gene expression (4)
- replication (4)
- Biogenese (3)
- Inhibitor (3)
- Onkolyse (3)
- RNS-Spleißen (3)
- Regulation (3)
- Replikationsursprung (3)
- Signaltransduktion (3)
- Transkriptionsfaktor (3)
- Translation <Genetik> (3)
- Tumor (3)
- angiogenesis (3)
- biochemistry (3)
- breast-tumors (3)
- metastasis (3)
- oncolysis (3)
- therapy (3)
- virotherapy (3)
- ALS (2)
- Biochemie (2)
- Biotransformation (2)
- Breast-tumors (2)
- CIP2A (2)
- DNA replication (2)
- DNS-Reparatur (2)
- Endoribonuklease P (2)
- Expression (2)
- Genexpression (2)
- Herpesvirus (2)
- Immunotherapy (2)
- Immunsuppression (2)
- In-vivo (2)
- Initiation (2)
- Interaktion (2)
- LARP4B (2)
- Lung cancer (2)
- Lungenkrebs (2)
- Messenger-RNS (2)
- NO (2)
- Nude-mice (2)
- ORC (2)
- PRMT5 (2)
- Prostatakrebs (2)
- RNase P (2)
- Saccharomyces cerevisiae (2)
- Schizophrenie (2)
- Schizosaccharomyces pombe (2)
- Spleißosom (2)
- Therapy (2)
- Transcription (2)
- USP28 (2)
- VACV (2)
- Virotherapy (2)
- Zebrabärbling (2)
- Zebrafisch (2)
- Zelldifferenzierung (2)
- adenovirus (2)
- biotransformation (2)
- blood (2)
- breast cancer (2)
- cancer treatment (2)
- cell cycle (2)
- electron microscopy (2)
- elongation (2)
- fusion and fission (2)
- in vitro (2)
- infection (2)
- inflammation (2)
- innate immunity (2)
- latency (2)
- lymph nodes (2)
- malignant melanoma (2)
- miR-30 (2)
- miRNA processing (2)
- microarray (2)
- microenvironment (2)
- mitochondria (2)
- mouse models (2)
- nude-mice (2)
- oncolytic viruses (2)
- onkolytische Virotherapie (2)
- p97 (2)
- protein (2)
- präreplikativer Komplex (2)
- reporter gene (2)
- schizophrenia (2)
- translation (2)
- tumors (2)
- type I interferon (2)
- vaccinia (2)
- virus reactivation (2)
- zebrafish (2)
- 26S proteasome (1)
- 7SK RNA (1)
- AD5 mutation (1)
- ADSC (1)
- ATG proteins (1)
- ATG12-ATG5 conjugate (1)
- ATP-Abhängigkeit (1)
- ATP-dependent (1)
- Activation (1)
- AdMSC (1)
- Agent (1)
- Aktin Zytoskelett (1)
- Allergie (1)
- Allergy (1)
- Allgemeine Entzündungsreaktion (1)
- Arabidopsis (1)
- Assembly (1)
- BRET (1)
- BRM (1)
- BV-2 (1)
- Biene (1)
- Bierhefe (1)
- Biolumineszenz-Resonanzenergie-Transfer (1)
- Biomarker (1)
- Biopolymere (1)
- Bisphenol A (1)
- Blood-brain barrier (1)
- Bose–Einstein condensates (1)
- Brahma (1)
- Breast-cancer (1)
- Bäckerhefe (1)
- C-MYC (1)
- CCR4 (1)
- CD9 (1)
- CDT1 (1)
- CGG repeat (1)
- CLIP-seq (1)
- COX-2 (1)
- CPG Island (1)
- CXorf44 (1)
- Catalyst (1)
- Ccr4-Not (1)
- Cdc48 (1)
- Cdc6 (1)
- Cell cycle (1)
- Cervix carcinoma (1)
- Cervix-Karzinom (1)
- Chaperone (1)
- Chemische Biologie (1)
- Chemotherapie (1)
- Chemotherapy (1)
- Chinese family (1)
- Chromatin-remodeling complexes (1)
- Cofaktor (1)
- Combination therapy (1)
- Cortical Actin Cytoskeleton (1)
- Costimulation (1)
- Cyclo-GMP (1)
- Cyclophosphamide (1)
- DHX30 (1)
- DNA Sekundärstruktur (1)
- DNA damage repair (1)
- DNA helicase (1)
- DNA secondary structure (1)
- DNA-Replication (1)
- DNA-replication (1)
- DNS-Bindungsproteine (1)
- DSMA1 (1)
- DUB (1)
- Daidzein (1)
- Darmkrebs (1)
- Dendritische Zelle (1)
- Dendritische Zellen (1)
- Differentiation (1)
- Dihydroisochinolinderivate (1)
- Dihydroisochinolinonderivate (1)
- Disease (1)
- Distinct (1)
- Elongation (1)
- Endosom (1)
- Endothelial Cell-Cell Contacts (1)
- Endotheliale Zell-Zell-Kontakte (1)
- Enzym (1)
- Enzyme (1)
- Eotaxin (1)
- Eukaryoten (1)
- Exons (1)
- FAM104A (1)
- FAM104B (1)
- FLIP (1)
- FLJ14775 (1)
- FLJ20434 (1)
- FMR1 (1)
- FMR2 (1)
- FMRP (1)
- FRAP (1)
- FXR1 (1)
- FXR2 (1)
- Factor gene PRPF31 (1)
- Fluorkohlenwasserstoffe (1)
- Fragiles-X-Syndrom (1)
- G-Protein-gekoppelter Rezeptor (1)
- G-Proteine (1)
- G-protein-coupled receptor (1)
- G-quadruplex motifs (1)
- G3BP (1)
- GBM (1)
- GLV-1H68 (1)
- Geminin (1)
- Gen notch (1)
- Genanalyse (1)
- Gene Expression (1)
- Gene-expression (1)
- Genes (1)
- Genexpressionsmaschinerie (1)
- Gliom (1)
- Glioma (1)
- Grad-seq (1)
- HFC245fa (1)
- HHV-6 (1)
- HHV-6A (1)
- HRAS (1)
- Hautuebertragung Lepra (1)
- Hepatitis (1)
- Hepatitis-C-Virus (1)
- Herz (1)
- Heterochromatin Protein 1 (1)
- Hitzeschockproteine (1)
- Homebox gene (1)
- Honigbiene (1)
- Hsc70 (1)
- Human Sodium/Iodide symporter (1)
- Human and murine cancer cells (1)
- Hundetumor (1)
- Hyper-IL-6 (1)
- IF2 (1)
- IGHMBP2 (1)
- IL-4 (1)
- IMA2.1 (1)
- IN-VIVO (1)
- Ifn-gamma (1)
- Immunisierung (1)
- Immunity (1)
- Immunpräzipitationen (1)
- Immunreaktion (1)
- Immunstimulation (1)
- Immunsystem (1)
- Impfung (1)
- In-Vivo (1)
- Initiation der DNA Replikation (1)
- Initiationsproteine der Maus (1)
- Interleukin 13 (1)
- Interleukin 4 (1)
- Interleukin 6 (1)
- Interleukin IL-6 (1)
- Interleukin-4 (1)
- Iron-uptake (1)
- Katalysator (1)
- Kombinationstherapie (1)
- Krebsbildgebung (1)
- LARP7 (1)
- LC3 lipidation (1)
- La Protein (1)
- La protein (1)
- Lepra (1)
- Leukozyt (1)
- Lokalisation (1)
- Lysozym (1)
- Lysozyme (1)
- MCM (1)
- MDSCs (1)
- MLLE domain (1)
- MMP-9 (1)
- MRI (1)
- MRI reporter (1)
- MVA (1)
- MYC (1)
- Macromolecular Assembly (1)
- Macromolecular Complex (1)
- Macromolecular Crystallography (1)
- Makromolekül (1)
- Malignant effusion (1)
- Maschine (1)
- Masern Virus (1)
- Masernvirus (1)
- Megakaryocytes (1)
- Megakaryozyt (1)
- Megakaryozyten (1)
- Melanom (1)
- Melanoma B16 (1)
- Messenger-RNP (1)
- Metabolismus (1)
- Metabonomix (1)
- Methylierung (1)
- Mice (1)
- Microarray (1)
- Mitomycin C (1)
- Molecular Chaperone (1)
- Molecular Machine (1)
- Molecular neuroscience (1)
- Molekulargenetik (1)
- MscS (1)
- Multiple drug resistance (1)
- Multiples Myelom (1)
- Multiproteinkomplex (1)
- Mutations (1)
- Myc (1)
- Mycobacterium leprae (1)
- Mykobakterien (1)
- Myoferlin (1)
- NA+/I-symporter (1)
- NA/I symporter (1)
- NEDMIAL (1)
- NMR-Tomographie (1)
- Neural precursor cells (1)
- Neuroblastoma (1)
- Neurodevelopmental diseases (1)
- Neurogenese (1)
- OSC (1)
- Oncolysis (1)
- Oncolytic action (1)
- Oncolytic vaccinia virus (1)
- Oncolytic virotherapy (1)
- Onkolytische Virotherapie (1)
- Orc2 (1)
- Origin (1)
- Origin of Recognition (1)
- P-TEFb (1)
- P97 (1)
- PABC1 (1)
- PABP (1)
- PABPC1 (1)
- PAM2 (1)
- PAM2w (1)
- PAR-CLIP (1)
- PAX genes (1)
- PAX-Gene (1)
- PDZ-Domäne (1)
- PDZ-domain (1)
- PGAS (1)
- PP2A (1)
- PRPF31 (1)
- PSD-95 (1)
- Pathogenese (1)
- Pathway (1)
- Pescadillo (1)
- Pflanzen (1)
- Phytoöstrogen (1)
- Phytoöstrogene (1)
- Plastide (1)
- Plastiden (1)
- Platelets (1)
- Plattenepithelkarzinom (1)
- Plättchen (1)
- Pockenviren (1)
- Pol II (1)
- Poly(A) binding protein (1)
- Polypeptidketten bindende Proteine (1)
- Poxviridae (1)
- Prochlorococcus marinus (1)
- Progenitor cells (1)
- Proliferation (1)
- Promotor (1)
- Promotor <Genetik> (1)
- Promotorpolymorphismus (1)
- Protein (1)
- Protein purification (1)
- Protein-Protein-Interaktionen (1)
- Proteinbiosynthese (1)
- Proteins (1)
- Pseudomonas (1)
- Pseudomonas aeruginosa (1)
- Quadruplex-DNS (1)
- RAB GTPases (1)
- RACK1 (1)
- REST (1)
- RNA (1)
- RNA Helicase (1)
- RNA Helikase (1)
- RNA Spleißen (1)
- RNA binding protein (1)
- RNA helicase (1)
- RNA metabolism (1)
- RNA splicing (1)
- RNA-Polymerase (1)
- RNA-binding proteins (1)
- RNA-polymerase-II (1)
- RNS-Ligase (1)
- ROS (1)
- RP11 (1)
- Ratte (1)
- Reaktionsmechanismus (1)
- Reaktive Sauerstoffspezies (1)
- Relaxin (1)
- Reporter gene (1)
- Retinitis pigmentosa (1)
- Retinitis pigmentosa (RP) (1)
- Retinoblastoma Protein (1)
- Retinoic acid (1)
- Retinopathia pigmentosa (1)
- Rezeptor (1)
- Ribonucleoproteine (1)
- Ribozym (1)
- SM proteins (1)
- SMA (1)
- SMARD1 (1)
- SP117 mutation (1)
- STAT (1)
- STAT3 (1)
- Saccharomyces cerevisiae telomeres (1)
- Salmonella-typhimurium (1)
- Schizophrenieerkrankung (1)
- Sekundärstruktur (1)
- Signalweg (1)
- Small angle X-ray scattering (1)
- Somatostatin (1)
- Somatostatinrezeptor Subtyp 4 (1)
- Spectrin (1)
- Spektrin (1)
- Spinale Muskelatrophie (1)
- Spleißen (1)
- Squamous cell carcinoma (1)
- Stat6 (1)
- Stattic (1)
- Stickstoffmonoxid (1)
- Stoffwechsel (1)
- Strahlentherapie (1)
- Struktur (1)
- Substratbindung (1)
- Subunit (1)
- Sugar-transport (1)
- Survival Motor Neuron (1)
- T cells (1)
- T-Lymphozyt (1)
- T-Zellen (1)
- T-cells (1)
- T-lymphocytes (1)
- TDRD3 (1)
- TIAR (1)
- TOP mRNA (1)
- TOP3b (1)
- TRI-SNRNP (1)
- TTF complex (1)
- Talg (1)
- Talganalyse (1)
- Terminal Oligopyrimidine Tract (1)
- Therapie (1)
- Thrombozyt (1)
- Thrombozytopenie (1)
- Tiermodell (1)
- Tissue (1)
- Toxikokinetik (1)
- Toxikologie (1)
- Transfer-RNS (1)
- Transgenic zebrafish (1)
- Transkription (1)
- Translation (1)
- Translationsinitiation (1)
- Translationskontrolle (1)
- Transporter (1)
- Trifluorpropionsäure (1)
- Trithorax (1)
- Tumor detection (1)
- Tumordetektion (1)
- Tumorimmunologie (1)
- Tumortherapie (1)
- Tumour (1)
- Two-Hybrid-System (1)
- UBXD1 (1)
- UKZ (1)
- Ubiquitin (1)
- United States (1)
- UsnRNP (1)
- VASP (1)
- VEGF (1)
- VSD (1)
- Vaccinia Virus (1)
- Vaccinia Virus Replikation (1)
- Vaccinia virus (VACV) (1)
- Vakzinia (1)
- Vascular endothelial Growth Factor (1)
- Ventrikelseptumdefekt (1)
- Virotherapie (1)
- Voronoi tree map (1)
- Wilms tumor (1)
- Wirtsfaktoren Lepra (1)
- X-ray crystallography (1)
- Xenoöstrogene (1)
- YAP5SA (1)
- YnaI (1)
- Zellbiologie (1)
- Zellskelett (1)
- Zellzyklus (1)
- Zellzyklus-Kontrolle (1)
- Zytoskelett (1)
- acute myeloid leukemia (1)
- adaptive immunity (1)
- alleles (1)
- aminocoumarins (1)
- animal model (1)
- animal-model (1)
- antibody production (1)
- antigen expression (1)
- antitumor immune response (1)
- antiviral immunity (1)
- apoptosis (1)
- aquired resistance (1)
- arginine methylation (1)
- arlR (1)
- ascites (1)
- assembly chaperone (1)
- autophagosome formation (1)
- autophagy (1)
- bacteriophage (1)
- binding (1)
- binding sites (1)
- bioluminescence resonance energy transfer (1)
- biomarkers (1)
- bisphenol A (1)
- bladder cancer (1)
- blastemal (1)
- bone morphogenetic protein (BMP) (1)
- boolean modeling (1)
- buparlisib (1)
- c-MYC (1)
- cGMP (1)
- cancer stem cells (CSCs) and differentiation (1)
- cancer therapy (1)
- canine and feline cancer therapy (1)
- canine cancer cell lines (1)
- canine cancer therapy (1)
- canine soft tissue sarcoma (CSTS) (1)
- canine tumor (1)
- carcinoma (1)
- cell biology (1)
- cell carcinoma (1)
- cell cultures (1)
- cell cycle control (1)
- cell migration (1)
- cell-line (1)
- chemical biology (1)
- chromatin (1)
- class I (1)
- clinical trial (1)
- colon cancer (1)
- colorectal (1)
- coloteral cancer (1)
- combination therapy (1)
- comparative genomic hybridization (1)
- complexity (1)
- costimulation (1)
- ctdsp2 (1)
- cyanelle (1)
- cytolysis (1)
- cytoskeleton (1)
- daidzein (1)
- delipidation (1)
- dendritic cells (1)
- density gradient centrifugation (1)
- differential centrifugation (1)
- diversity (1)
- dogs (1)
- dominant-negative (1)
- down regulation (1)
- electron cryomicroscopy (1)
- endoplasmic reticulum (1)
- endothelial growth-factor (1)
- engineered measles-virus (1)
- enzyme (1)
- epithelial-mesenchymal transition (1)
- evolutionary genetics (1)
- expression (1)
- family (1)
- fluorescence imaging (1)
- fluorescence microscopy (1)
- fraxe mental retardation (1)
- gefitinib (1)
- gene-therapy (1)
- genes (1)
- genetic interactions (1)
- genome instability (1)
- genome stability (1)
- genomics (1)
- glioblastoma multiforme (GBM) (1)
- glv-1h68 (1)
- granulophagy (1)
- granulostasis (1)
- gyrase (1)
- haploinsufficiency (1)
- heart (1)
- hepatitis (1)
- hepatitis C virus (1)
- heterochromatin protein 1 (1)
- hey (1)
- histology (1)
- hnscc (1)
- honeybee (1)
- host factors leprosy (1)
- human xenografted mouse models (1)
- humanized tumor (1)
- hydrofluorocarbons (1)
- iNOS (1)
- immunisation (1)
- immunity (1)
- immunoprecipitation (1)
- immunosuppression (1)
- immunotherapy (1)
- immunotherapy of cancer (1)
- immunprecipitations (1)
- in vivo imaging (1)
- in-vitro (1)
- in-vitro propagation (1)
- inhibition (1)
- initiation (1)
- initiation of DNA-replication (1)
- initiation proteins of mouse (1)
- initiator-tRNA (1)
- innate immune system (1)
- interacting proteins (1)
- interaction (1)
- interagierende Proteine (1)
- interleukin-4 (1)
- ionizing radiation (1)
- kidneys (1)
- label-free quantification (1)
- length (1)
- leukocyte (1)
- lines (1)
- living cells (1)
- localization (1)
- luciferase (1)
- lung and intrathoracic tumors (1)
- lung cancer (1)
- lysozyme (1)
- m-RNA (1)
- mRNA-Metabolismus (1)
- macrophages (1)
- magnetic resonance imaging (1)
- males (1)
- malignant pleural mesothelioma (1)
- mass spectrometry (1)
- matrix metalloproteinases (1)
- measles virus (1)
- mechanosensing (1)
- mechanosensitive channels (1)
- melanoma (1)
- membrane (1)
- messenger RNA (1)
- metabolism (1)
- metabonomics (1)
- metastatic tumors (1)
- methionine (1)
- miR-181 (1)
- miR-26b (1)
- miRNA (1)
- miRNS (1)
- mice (1)
- microglia (1)
- microvascular density (1)
- model (1)
- molecular evolution (1)
- molecular imaging (1)
- motile phenotype (1)
- motor-neuron protein (1)
- mouse model (1)
- murine (1)
- mva (1)
- neutrophils (1)
- niedermolekularer Inhibitor (1)
- noncoding RNA (1)
- nonlinear optics (1)
- notch (1)
- novobiocin (1)
- nuclear import (1)
- nude mice (1)
- oncogenic YAP (1)
- oncolytic vaccinia virus (1)
- oncolytic virus therapy (1)
- onkolytische Virustherapie (1)
- onkolytisches Virus (1)
- organellar mapping (1)
- origin (1)
- p97 VCP Cdc48 (1)
- p97/VCP (1)
- pICln (1)
- pancreatic cancer (1)
- panel (1)
- partial purification (1)
- permutation (1)
- peroxisome purification (1)
- pet dogs (1)
- pflanzliche Zellkerne (1)
- phage (1)
- phase transition (1)
- phosphatases (1)
- phytoestrogens (1)
- plant nuclei (1)
- plastids (1)
- polarization (1)
- polymorphism (1)
- positron-emission-tomography (1)
- posttranscriptional gene regulation (1)
- pre-mRNA splicing (1)
- pre-replicative complex (1)
- pre-tRNA Spleißen (1)
- pre-tRNA splicing (1)
- preRC (1)
- prereplicative complex (1)
- prognostic biomarkers (1)
- prognostic relevance (1)
- proliferation (1)
- promoter (1)
- promoter polymorphism (1)
- proppins (1)
- prostate (1)
- prostate cancer (1)
- protein argentine methyltranserase (1)
- protein localization (1)
- protein subunit (1)
- protein-lipid interactions (1)
- protein-protein-interactions (1)
- proteins (1)
- präRC (1)
- quality control (1)
- receptor (1)
- recognition (1)
- regressive (1)
- renal cancer (1)
- replicating adenovirus (1)
- restriction (1)
- retinobalstoma protein (1)
- ribonuclease-P (1)
- ribosome (1)
- ribosome profiling (1)
- ribozyme (1)
- rod degeneration (1)
- rs112587690 (1)
- rs12628 (1)
- sDMA (1)
- sebum (1)
- sebum analysis (1)
- secondary lung tumors (1)
- separation (1)
- sequence (1)
- signaltransduction (1)
- skin transmission leprosy (1)
- small molecule inhibitor (1)
- snRNP (1)
- snRNPs (1)
- somatostatin receptor subtype 4 (1)
- spacer (1)
- spatial proteomics (1)
- splicing defect (1)
- splicing factor (1)
- staphylococcus aureus (1)
- stem Cells (1)
- stem cells (1)
- stromal vascular fraction (1)
- subcutaneous human tumors (1)
- subpopulation (1)
- substrate binding (1)
- supercoiling (1)
- tRNA Ligase (1)
- tRNA Reparatur (1)
- tRNA ligase (1)
- tRNA repair (1)
- target (1)
- terminal differentiation (1)
- terminale Differenzierung (1)
- tissue microarray (1)
- toxicokinetics (1)
- transcription (1)
- translational regulation (1)
- trifluoropropionic acid (1)
- tumor immunology (1)
- tumor microenvironment (1)
- tumor therapy (1)
- two-hybrid-system (1)
- ubiquitin proteasome system (1)
- up-regulation (1)
- vaccination (1)
- vaccinia virus (VACV) (1)
- vaccinia virus replication (1)
- vemurafenib (1)
- viral replication (1)
- viral therapy (1)
- xenoestrogens (1)
- yeast telomerase (1)
- zinc-finger (1)
- ΔNp63 (1)
Institute
- Lehrstuhl für Biochemie (121)
- Rudolf-Virchow-Zentrum (12)
- Theodor-Boveri-Institut für Biowissenschaften (10)
- Graduate School of Life Sciences (9)
- Institut für Molekulare Infektionsbiologie (9)
- Institut für Virologie und Immunbiologie (3)
- Physikalisches Institut (3)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Medizinische Klinik und Poliklinik I (2)
Schriftenreihe
Sonstige beteiligte Institutionen
- CIBSS Centre for Integrative Biological Signalling Studies, University of Freiburg (1)
- Genelux Corporation, San Diego Science Center, 3030 Bunker Hill Street, Suite 310, San Diego, California 92109, USA (1)
- MRB Forschungszentrum für Magnet-Resonanz-Bayern e.V., Am Hubland, D-97074 Würzburg (1)
- Rudolf-Virchow-Zentrum DFG-Forschungszentrum für Experimentelle Biomedizin der Universität Würzburg (1)
The eukaryotic gene expression requires extensive regulations to enable the homeostasis of the cell and to allow dynamic responses due to external stimuli. Although many regulatory mechanisms involve the transcription as the first step of the gene expression, intensive regulation occurs also in the post-transcriptional mRNA metabolism. Thereby, the particular composition of the mRNPs plays a central role as the components associated with the mRNA form a specific “mRNP code” which determines the fate of the mRNA. Many proteins which are involved in this regulation and the mRNA metabolism are affected in diseases and especially neurological disorders often result from an aberrant mRNP code which leads to changes in the regulation and expression of mRNPs.
The focus of this work was on a trimeric protein complex which is termed TTF complex based on its subunits TDRD3, TOP3β and FMRP. Biochemical investigations revealed that the three components of the TTF complex are nucleo-cytosolic shuttle proteins which localize in the cytoplasm at the steady-state, associate with mRNPs and are presumably connected to the translation. Upon cellular stress conditions, the TTF components concentrate in stress granules. Thus, the TTF complex is part of the mRNP code, however its target RNAs and function are still completely unknown. Since the loss of functional FMRP results in the fragile X syndrome and TOP3β is associated with schizophrenia and intellectual disability, the TTF complex connects these phenotypically related neuro-psychiatric disorders with each other on a molecular level.
Therefore, the aim of this work was to biochemically characterize the TTF complex and to define its function in the mRNA metabolism. In this work, evidence was provided that TDRD3 acts as the central unit of the TTF complex and directly binds to FMRP as well as to TOP3β. Thereby, the interaction of TDRD3 and TOP3β is very stable, whereas FMRP is a dynamic component. Interestingly, the TTF complex is not bound directly to mRNA, but is recruited via the exon junction complex (EJC) to mRNPs. This interaction is mediated by a specific binding motif of TDRD3, the EBM. Upon biochemical and biological investigations, it was possible to identify the interactome of the TTF complex and to define the role in the mRNA metabolism. The data revealed that the TTF complex is mainly associated with “early” mRNPs and is probably involved in the pioneer round of translation. Furthermore, TOP3β was found to bind directly to the ribosome and thus, establishes a connection between the EJC and the translation machinery. A reduction of the TTF components resulted in selective changes in the proteome in cultured cells, whereby individual protein subsets seem to be regulated rather than the global protein expression.
Moreover, the enzymatic analysis of TOP3β indicated that TOP3β is a type IA topoisomerase which can catalytically attack not only DNA but also RNA. This aspect is particularly interesting with regard to the connection between early mRNPs and the translation which has been revealed in this work.
The data obtained in this work suggest that the TTF complex plays a role in regulating the metabolism of an early mRNP subset possibly in the course of the pioneer round of translation. Until now, the link between an RNA topoisomerase and the mRNA metabolism is thereby unique and thus provides a completely new perspective on the steps in the post-transcriptional gene expression and its regulation.
Background
The mechanisms by which vaccinia virus (VACV) interacts with the innate immune components are complex and involve different mechanisms. iNOS-mediated NO production by myeloid cells is one of the central antiviral mechanisms and this study aims to investigate specifically whether iNOS-mediated NO production by myeloid cells, is involved in tumor eradication following the virus treatment.
Methods
Human colon adenocarcinoma (HCT-116) xenograft tumors were infected by VACV. Infiltration of iNOS\(^{+}\) myeloid cell population into the tumor, and virus titer was monitored following the treatment. Single-cell suspensions were stained for qualitative and quantitative flow analysis. The effect of different myeloid cell subsets on tumor growth and colonization were investigated by depletion studies. Finally, in vitro culture experiments were carried out to study NO production and tumor cell killing. Student’s t test was used for comparison between groups in all of the experiments.
Results
Infection of human colon adenocarcinoma (HCT-116) xenograft tumors by VACV has led to recruitment of many CD11b\(^{+}\) ly6G\(^{+}\) myeloid-derived suppressor cells (MDSCs), with enhanced iNOS expression in the tumors, and to an increased intratumoral virus titer between days 7 and 10 post-VACV therapy. In parallel, both single and multiple rounds of iNOS-producing cell depletions caused very rapid tumor growth within the same period after virus injection, indicating that VACV-induced iNOS\(^{+}\) MDSCs could be an important antitumor effector component. A continuous blockade of iNOS by its specific inhibitor, L-NIL, showed similar tumor growth enhancement 7–10 days post-infection. Finally, spleen-derived iNOS+ MDSCs isolated from virus-injected tumor bearing mice produced higher amounts of NO and effectively killed HCT-116 cells in in vitro transwell experiments.
Conclusions
We initially hypothesized that NO could be one of the factors that limits active spreading of the virus in the cancerous tissue. In contrast to our initial hypothesis, we observed that PMN-MDSCs were the main producer of NO through iNOS and NO provided a beneficial antitumor effect, The results strongly support an important novel role for VACV infection in the tumor microenvironment. VACV convert tumor-promoting MDSCs into tumor-killing cells by inducing higher NO production.
Background
Tumour resistance to a wide range of drugs (multiple drug resistant, MDR) acquired after intensive chemotherapy is considered to be the main obstacle of the curative treatment of cancer patients. Recent work has shown that oncolytic viruses demonstrated prominent potential for effective treatment of diverse cancers. Here, we evaluated whether genetically modified vaccinia virus (LIVP-GFP) may be effective in treatment of cancers displaying MDR phenotype.
Methods
LIVP-GFP replication, transgene expression and cytopathic effects were analysed in human cervical carcinomas KB-3-1 (MDR−), KB-8-5 (MDR+) and in murine melanoma B-16 (MDR−), murine lymphosarcomas RLS and RLS-40 (MDR+). To investigate the efficacy of this therapy in vivo, we treated immunocompetent mice bearing murine lymphosarcoma RLS-40 (MDR+) (6- to 8-week-old female CBA mice; n = 10/group) or melanoma B-16 (MDR−) (6- to 8-week-old female C57Bl mice; n = 6/group) with LIVP-GFP (5 × 107 PFU of virus in 0.1 mL of IMDM immediately and 4 days after tumour implantation).
Results
We demonstrated that LIVP-GFP replication was effective in human cervical carcinomas KB-3-1 (MDR−) and KB-8-5 (MDR+) and in murine melanoma B-16 (MDR−), whereas active viral production was not detected in murine lymphosarcomas RLS and RLS-40 (MDR+). Additionally, it was found that in tumour models in immunocompetent mice under the optimized regimen intratumoural injections of LIVP-GFP significantly inhibited melanoma B16 (33 % of mice were with complete response after 90 days) and RLS-40 tumour growth (fourfold increase in tumour doubling time) as well as metastasis.
Conclusion
The anti-tumour activity of LIVP-GFP is a result of direct oncolysis of tumour cells in case of melanoma B-16 because the virus effectively replicates and destroys these cells, and virus-mediated activation of the host immune system followed by immunologically mediated destruction of of tumour cells in case of lymphosarcoma RLS-40. Thus, the recombinant vaccinia virus LIVP-GFP is able to inhibit the growth of malignant cells with the MDR phenotype and tumour metastasis when administered in the early stages of tumour development.
Wilms tumor (WT) is the most common childhood renal cancer. Recent findings of mutations in microRNA (miRNA) processing proteins suggest a pivotal role of miRNAs in WT genesis. We performed miRNA expression profiling of 36 WTs of different subtypes and four normal kidney tissues using microarrays. Additionally, we determined the gene expression profile of 28 of these tumors to identify potentially correlated target genes and affected pathways. We identified 85 miRNAs and 2107 messenger RNAs (mRNA) differentially expressed in blastemal WT, and 266 miRNAs and 1267 mRNAs differentially expressed in regressive subtype. The hierarchical clustering of the samples, using either the miRNA or mRNA profile, showed the clear separation of WT from normal kidney samples, but the miRNA pattern yielded better separation of WT subtypes. A correlation analysis of the deregulated miRNA and mRNAs identified 13,026 miRNA/mRNA pairs with inversely correlated expression, of which 2844 are potential interactions of miRNA and their predicted mRNA targets. We found significant upregulation of miRNAs-183, -301a/b and -335 for the blastemal subtype, and miRNAs-181b, -223 and -630 for the regressive subtype. We found marked deregulation of miRNAs regulating epithelial to mesenchymal transition, especially in the blastemal subtype, and miRNAs influencing chemosensitivity, especially in regressive subtypes. Further research is needed to assess the influence of preoperative chemotherapy and tumor infiltrating lymphocytes on the miRNA and mRNA patterns in WT
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a promising approach for cancer therapy. Recently, we showed that the oncolytic vaccinia virus GLV-1h68 has a therapeutic potential in treating human prostate and hepatocellular carcinomas in xenografted mice. In this study, we describe the use of dynamic boolean modeling for tumor growth prediction of vaccinia virus-injected human tumors. Antigen profiling data of vaccinia virus GLV-1h68-injected human xenografted mice were obtained, analyzed and used to calculate differences in the tumor growth signaling network by tumor type and gender. Our model combines networks for apoptosis, MAPK, p53, WNT, Hedgehog, the T-killer cell mediated cell death, Interferon and Interleukin signaling networks. The in silico findings conform very well with in vivo findings of tumor growth. Similar to a previously published analysis of vaccinia virus-injected canine tumors, we were able to confirm the suitability of our boolean modeling for prediction of human tumor growth after virus infection in the current study as well. In summary, these findings indicate that our boolean models could be a useful tool for testing of the efficacy of VACV-mediated cancer therapy already before its use in human patients.
The CCHC-type zinc finger nucleic acid-binding protein (CNBP/ZNF9) is conserved in eukaryotes and is essential for embryonic development in mammals. It has been implicated in transcriptional, as well as post-transcriptional, gene regulation; however, its nucleic acid ligands and molecular function remain elusive. Here, we use multiple systems-wide approaches to identify CNBP targets and function. We used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) to identify 8,420 CNBP binding sites on 4,178 mRNAs. CNBP preferentially bound G-rich elements in the target mRNA coding sequences, most of which were previously found to form G-quadruplex and other stable structures in vitro. Functional analyses, including RNA sequencing, ribosome profiling, and quantitative mass spectrometry, revealed that CNBP binding did not influence target mRNA abundance but rather increased their translational efficiency. Considering that CNBP binding prevented G-quadruplex structure formation in vitro, we hypothesize that CNBP is supporting translation by resolving stable structures on mRNAs.
Oncolytic vaccinia virus (VACV) therapy is an alternative cancer treatment modality that mediates targeted tumor destruction through a tumor-selective replication and an induction of anti-tumor immunity. We developed a humanized tumor mouse model with subcutaneous human tumors to analyze the interactions of VACV with the developing tumors and human immune system. A successful systemic reconstitution with human immune cells including functional T cells as well as development of tumors infiltrated with human T and natural killer (NK) cells was observed. We also demonstrated successful in vivo colonization of such tumors with systemically administered VACVs. Further, a new recombinant GLV-1h376 VACV encoding for a secreted human CTLA4-blocking single-chain antibody (CTLA4 scAb) was tested. Surprisingly, although proving CTLA4 scAb’s in vitro binding ability and functionality in cell culture, beside the significant increase of CD56\(^{bright}\) NK cell subset, GLV-1h376 was not able to increase cytotoxic T or overall NK cell levels at the tumor site. Importantly, the virus-encoded β-glucuronidase as a measure of viral titer and CTLA4 scAb amount was demonstrated. Therefore, studies in our “patient-like” humanized tumor mouse model allow the exploration of newly designed therapy strategies considering the complex relationships between the developing tumor, the oncolytic virus, and the human immune system.
Einhergehend mit einer steigenden Lebenserwartung nimmt auch die Zahl der am Multiplen Myelom Erkrankten zu. Bis dato gibt es nur wenige Therapieansätze dieser selten vorkommenden Blutkrebserkrankung. Im Zusammenhang mit der Entstehung des Multiplen Myeloms stehen vor allem zwei bedeutende Hitzeschockproteine: Hsp90 und Hsp70. Beide haben die Aufgabe, Zellen vor Apoptose zu schützen. In proliferierenden Plasmazellen ist eine Überexpression an Hsp90 zu beobachten. Entwickelte Inhibitoren führten zwar zu einer verminderten Hsp90-Aktivität, allerdings wurde diese durch eine vermehrte Expression von Hsp70 kompensiert, weshalb Myelomzellen weiterhin proliferierten. Aus diesem Grund bietet sich Hsp70 als weiterer Angriffspunkt in der Therapierung des Multiplen Myeloms an. Die bislang entwickelten Inhibitoren binden entweder an die Nukleotid- oder Substratbindedomäne. Da beide Stellen unspezifisch sind, wurden durch virtuelles Screening potenzielle Inhibitoren für Hsp70 identifiziert, welche in vitro und in vivo tatsächlich Effekte hinsichtlich der Herunterregulierung von Hsp70 zeigten. Ob die entwickelten Substanzen jedoch direkt an Hsp70 binden, war die Fragestellung der vorliegenden Arbeit.
In dieser Arbeit wurde untersucht, inwiefern die entwickelten Inhibitoren an Hsp70 binden und dieses inhibieren. Die humane Hsp70-Familie besitzt sechzehn Mitglieder, die alle ähnliche Aufgaben und Strukturmerkmale aufweisen. Für die durchgeführten Versuche wurde die Hsp70-Isoform Hsc70 verwendet. In einem Protein-Ligand-Assay konnte gezeigt werden, dass die meisten Verbindungen durch Aggregatbildung zu einer Inhibition von Hsc70 führten. Durch Zugabe von Detergenz konnten die gebildeten Aggregate aufgebrochen und so der Inhibitionseffekt aufgehoben bzw. deutlich reduziert werden. Damit konnte gezeigt werden, dass die in Zell- und Mausversuchen beobachteten Effekte vermutlich nicht auf eine direkte Inhibition von Hsc70 zurückzuführen sind. Ob diese Effekte nun ebenfalls auf Aggregatbildung beruhen oder aber ein anderes Protein als das vermutete Hsc70 inhibiert wird, was über eine Signalkaskade zur Inhibition von Hsc70 führt, wäre eine interessante Fragestellung für weitere Untersuchungen.
Da sowohl in NMR-Versuchen als auch dem durchgeführten Protein-Ligand-Assay gezeigt werden konnte, dass die vormals als potenzielle Inhibitoren entwickelten Verbindungen nur schwach aktiv sind, wurde durch Fragment-basierte Ansätze eine andere Bindestelle für mögliche Inhibitoren identifiziert. Hierbei konnte N-Acetyl-D-Glucosamin in der Nukleotidbindedomäne von Hsc70 detektiert werden. Hieraus könnten sich neue Ansätze zur Entwicklung neuartiger in silico entwickelter Hsc70-Inhibitoren ergeben.
Ausgangspunkt für die Docking-Studien zur Entwicklung neuer Hsp70-Inhibitoren war die Kristallstruktur von bHsc70 ED 1-554, einer trunkierten Doppelmutante des nativen Hsc70. Bis dato ist diese 554 Aminosäuren umfassende Mutante die einzige Hsc70-Variante von der die Zweidomänenstruktur kristallisiert werden konnte. Für dieses Konstrukt wurde zunächst ein optimiertes Aufreinigungsprotokoll entwickelt, um dann Kristallisationsversuche mit ausgewählten AH-Verbindungen, die in den Docking-Studien entwickelt wurden, durchzuführen. Hierbei konnte jedoch keine Bindung festgestellt werden. Die Kristallisation mit Ver-155008, einem bekannten Hsc70-Inhibitor, führte jedoch zur ersten Zweidomänenstruktur von Hsc70 mit gebundenem Ver-155008.
Neben der obigen Fragestellung wurde außerdem untersucht, wie funktional aktiv das trunkierte Hsc70-Konstrukts ist. Hier zeigte sich, dass aufgrund des fehlenden C-Terminus zwar eine geringe Aktivität von 30 % im Vergleich zur Volllänge zu beobachten war. Für eine nahezu vollständige Rückfaltungsaktivität ist aber der C-Terminus essentiell. Weiterhin konnte in ITC-Versuchen der Kd-Wert von Ver-155008 an die verwendete Mutante ermittelt werden, der dem bereits bekannten Kd von Ver-155008 an das native Hsc70 ähnlich ist.
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In this study, we analyzed for the first time the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 in two human hepatocellular carcinoma cell lines HuH7 and PLC/PRF/5 (PLC) in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 efficiently colonized, replicated in, and did lyse these cancer cells in culture. Experiments with HuH7 and PLC xenografts have revealed that a single intravenous injection (i.v.) of mice with GLV-1h68 resulted in a significant reduction of primary tumor sizes compared to uninjected controls. In addition, replication of GLV-1h68 in tumor cells led to strong inflammatory and oncolytic effects resulting in intense infiltration of MHC class II-positive cells like neutrophils, macrophages, B cells and dendritic cells and in up-regulation of 13 pro-inflammatory cytokines. Furthermore, GLV-1h68 infection of PLC tumors inhibited the formation of hemorrhagic structures which occur naturally in PLC tumors. Interestingly, we found a strongly reduced vascular density in infected PLC tumors only, but not in the non-hemorrhagic HuH7 tumor model. These data demonstrate that the GLV-1h68 vaccinia virus may have an enormous potential for treatment of human hepatocellular carcinoma in man.
Die essenzielle, Ubiquitin-selektive ATPase p97 reguliert eine Vielzahl unterschiedlicher Prozesse in Eukaryoten. Dazu zählen Proteinqualitätskontrolle, DNA-Reparatur, Signaltransduktion, Zellzykluskontrolle, Autophagie sowie das endolysosomale System. Diese unterschiedlichen Funktionen von p97 werden durch die Bindung von Kofaktoren engmaschig gesteuert und kontrolliert. Die größte und am besten untersuchte Gruppe von p97-Kofaktoren sind die Proteine der UBX Familie. Diese zeichnen sich durch den Besitz einer UBX-Domäne aus, welche die Bindung an p97 vermittelt. Das in höheren Eukaryoten konservierte Familienmitglied UBXD1 besitzt darüber hinaus mit einer PUB-Domäne und einem VIM-Motiv noch mindestens zwei weitere p97-Bindemodule. UBXD1 kann an Vesikel des endolysosomalen Degradationssytems lokalisieren, seine genauen zellulären Funktionen sind jedoch noch weitgehend unbekannt.
Ziel dieser Arbeit war die funktionelle Charakterisierung von humanem UBXD1. Dafür wurden Kandidaten eines zuvor durchgeführten Yeast-Two-Hybrid-Screens auf ihre Two Hybrid-Interaktion mit unterschiedlichen UBXD1-Varianten getestet. Darüber hinaus wurde durch Immunpräzipitationsexperimente untersucht, ob die Kandidatenproteine auch in Säugerzellen mit UBXD1 interagieren. Als vielversprechende neue Bindungspartner von UBXD1 wurden so die Ubiquitin-Ligase TRIAD3A und das Ubiquitin-editierende Protein A20 identifiziert. Desweiteren konnte gezeigt werden, dass die Interaktion zwischen UBXD1 und A20 von einer funktionellen PUB Domäne und dem siebten Zinkfinger Motiv von A20 abhängig ist.
Da sowohl TRIAD3A als auch A20 negative Regulatoren des NF B Signalweges sind, wurde daraufhin untersucht, ob auch UBXD1 eine Funktion in diesem Signalweg besitzt. Tatsächlich war in UBXD1-depletierten HeLa 57A-Zellen die NF B-abhängige Expression eines Reportgens nach Aktivierung des Signalweges durch TNF, IL-1, Doxorubicin und H2O2 stark reduziert. Dabei spricht die verringerte Aktivierung nach unterschiedlichen Stimuli für eine generelle Rolle von UBXD1 im NF B Signalweg. Durch quantitative Echtzeit-PCR konnte gezeigt werden, dass in HeLa- und HEK293T-Zellen nach UBXD1-Depletion auch die Expression endogener NF B Zielgene verringert ist. Da in UBXD1-depletierten Zellen nach Stimulation mit TNF oder IL-1 bereits die Kerntranslokation des NF B-Transkriptionsfaktor p65 reduziert ist, ist davon auszugehen, dass UBXD1 an einer früheren Phase der Aktivierung des Signalweges beteiligt ist. Möglicherweise ist dies darauf zurückzuführen, dass UBXD1 bekannte Funktionen von A20 reguliert und etwa die Bindung von A20 an Vesikel des endolysosomalen Systems oder an lineare Ubiquitinketten beeinflusst. Diese Arbeit beschreibt somit eine neue Funktion des p97-Kofaktors UBXD1 im NF B-Signalweg.
Background:
Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.
Methods:
We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1 beta, a cytokines which is involved in the innate immune responses.
Results:
Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1b induced expression of cytokines of the innate immune responses.
Conclusions:
This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.
Background:
The SWI/SNF chromatin remodeling factors have the ability to remodel nucleosomes and play essential roles in key developmental processes. SWI/SNF complexes contain one subunit with ATPase activity, which in Drosophila melanogaster is called Brahma (Brm). The regulatory activities of SWI/SNF have been attributed to its influence on chromatin structure and transcription regulation, but recent observations have revealed that the levels of Brm affect the relative abundances of transcripts that are formed by alternative splicing and/or polyadenylation of the same pre-mRNA.
Results:
We have investigated whether the function of Brm in pre-mRNA processing in Drosophila melanogaster is mediated by Brm alone or by the SWI/SNF complex. We have analyzed the effects of depleting individual SWI/SNF subunits on pre-mRNA processing throughout the genome, and we have identified a subset of transcripts that are affected by depletion of the SWI/SNF core subunits Brm, Snr1 or Mor. The fact that depletion of different subunits targets a subset of common transcripts suggests that the SWI/SNF complex is responsible for the effects observed on pre-mRNA processing when knocking down Brm. We have also depleted Brm in larvae and we have shown that the levels of SWI/SNF affect the pre-mRNA processing outcome in vivo.
Conclusions:
We have shown that SWI/SNF can modulate alternative pre-mRNA processing, not only in cultured cells but also in vivo. The effect is restricted to and specific for a subset of transcripts. Our results provide novel insights into the mechanisms by which SWI/SNF regulates transcript diversity and proteomic diversity in higher eukaryotes.
Background:
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo.
Methods:
In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection.
Results:
We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection.
Conclusions:
Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.
Background:
Retinitis pigmentosa (RP) is an inherited eye disease characterized by the progressive degeneration of rod photoreceptor cells. Mutations in pre-mRNA splicing factors including PRPF31 have been identified as cause for RP, raising the question how mutations in general factors lead to tissue specific defects.
Results:
We have recently shown that the zebrafish serves as an excellent model allowing the recapitulation of key events of RP. Here we use this model to investigate two pathogenic mutations in PRPF31, SP117 and AD5, causing the autosomal dominant form of RP. We show that SP117 leads to an unstable protein that is mislocalized to the rod cytoplasm. Importantly, its overexpression does not result in photoreceptor degeneration suggesting haploinsufficiency as the underlying cause in human RP patients carrying SP117. In contrast, overexpression of AD5 results in embryonic lethality, which can be rescued by wild-type Prpf31. Transgenic retina-specific expression of AD5 reveals that stable AD5 protein is initially localized in the nucleus but later found in the cytoplasm concurrent with progressing rod outer segment degeneration and apoptosis. Importantly, we show for the first time in vivo that retinal transcripts are wrongly spliced in adult transgenic retinas expressing AD5 and exhibiting increased apoptosis in rod photoreceptors.
Conclusion:
Our data suggest that distinct mutations in Prpf31 can lead to photoreceptor degeneration through different mechanisms, by haploinsufficiency or dominant-negative effects. Analyzing the AD5 effects in our animal model in vivo, our data imply that aberrant splicing of distinct retinal transcripts contributes to the observed retina defects.
Telomerase, the enzyme that maintains telomeres, preferentially lengthens short telomeres. The S. cerevisiae Pif1 DNA helicase inhibits both telomerase-mediated telomere lengthening and de novo telomere addition at double strand breaks (DSB). Here, we report that the association of the telomerase subunits Est2 and Est1 at a DSB was increased in the absence of Pif1, as it is at telomeres, suggesting that Pif1 suppresses de novo telomere addition by removing telomerase from the break. To determine how the absence of Pif1 results in telomere lengthening, we used the single telomere extension assay (STEX), which monitors lengthening of individual telomeres in a single cell cycle. In the absence of Pif1, telomerase added significantly more telomeric DNA, an average of 72 nucleotides per telomere compared to the 45 nucleotides in wild type cells, and the fraction of telomeres lengthened increased almost four-fold. Using an inducible short telomere assay, Est2 and Est1 no longer bound preferentially to a short telomere in pif1 mutant cells while binding of Yku80, a telomere structural protein, was unaffected by the status of the PIF1 locus. Two experiments demonstrate that Pif1 binding is affected by telomere length: Pif1 (but not Yku80) -associated telomeres were 70 bps longer than bulk telomeres, and in the inducible short telomere assay, Pif1 bound better to wild type length telomeres than to short telomeres. Thus, preferential lengthening of short yeast telomeres is achieved in part by targeting the negative regulator Pif1 to long telomeres.
Background:
Recent studies have shown that human ferritin can be used as a reporter of gene expression for magnetic resonance imaging (MRI). Bacteria also encode three classes of ferritin-type molecules with iron accumulation properties.
Methods and Findings:
Here, we investigated whether these bacterial ferritins can also be used as MRI reporter genes and which of the bacterial ferritins is the most suitable reporter. Bacterial ferritins were overexpressed in probiotic E. coli Nissle 1917. Cultures of these bacteria were analyzed and those generating highest MRI contrast were further investigated in tumor bearing mice. Among members of three classes of bacterial ferritin tested, bacterioferritin showed the most promise as a reporter gene. Although all three proteins accumulated similar amounts of iron when overexpressed individually, bacterioferritin showed the highest contrast change. By site-directed mutagenesis we also show that the heme iron, a unique part of the bacterioferritin molecule, is not critical for MRI contrast change. Tumor-specific induction of bacterioferritin-expression in colonized tumors resulted in contrast changes within the bacteria-colonized tumors.
Conclusions:
Our data suggest that colonization and gene expression by live vectors expressing bacterioferritin can be monitored by MRI due to contrast changes.
Introduction:
Oncolytic viruses show promise for treating cancer. However, to assess therapeutic efficacy and potential toxicity, a noninvasive imaging modality is needed. This study aimed to determine if insertion of the human sodium iodide symporter (hNIS) cDNA as a marker for non-invasive imaging of virotherapy alters the replication and oncolytic capability of a novel vaccinia virus, GLV-1h153.
Methods:
GLV-1h153 was modified from parental vaccinia virus GLV-1h68 to carry hNIS via homologous recombination. GLV-1h153 was tested against human pancreatic cancer cell line PANC-1 for replication via viral plaque assays and flow cytometry. Expression and transportation of hNIS in infected cells was evaluated using Westernblot and immunofluorescence. Intracellular uptake of radioiodide was assessed using radiouptake assays. Viral cytotoxicity and tumor regression of treated PANC-1tumor xenografts in nude mice was also determined. Finally, tumor radiouptake in xenografts was assessed via positron emission tomography (PET) utilizing carrier-free (124)I radiotracer.
Results:
GLV-1h153 infected, replicated within, and killed PANC-1 cells as efficiently as GLV-1h68. GLV-1h153 provided dose-dependent levels of hNIS expression in infected cells. Immunofluorescence detected transport of the protein to the cell membrane prior to cell lysis, enhancing hNIS-specific radiouptake (P < 0.001). In vivo, GLV-1h153 was as safe and effective as GLV-1h68 in regressing pancreatic cancer xenografts (P < 0.001). Finally, intratumoral injection of GLV-1h153 facilitated imaging of virus replication in tumors via (124)I-PET.
Conclusion:
Insertion of the hNIS gene does not hinder replication or oncolytic capability of GLV-1h153, rendering this novel virus a promising new candidate for the noninvasive imaging and tracking of oncolytic viral therapy.
G-Quadruplex (G4)-Strukturen sind sehr stabile und polymorphe DNA und RNA Sekundärstrukturen mit einem konservierten Guanin-reichen Sequenzmotiv (G4-Motiv). Sie bestehen aus übereinander gestapelten planaren G-Quartetts, in denen je vier Guanine durch Wasserstoffbrückenbindungen zusammengehalten werden.
Da G4-Motive in Eukaryoten an bestimmten Stellen im Genom angereichert vorkommen, wird angenommen, dass die Funktion von G4-Strukturen darin besteht, biologische Prozesse positiv oder negativ zu regulieren. Aufgrund der hohen thermodynamischen Stabilität von G4 Strukturen ist davon auszugehen, dass Proteine in die Faltung, Stabilisierung und Entfaltung dieser Nukleinsäure-Strukturen regulatorisch involviert sind. Bis heute wurden viele Proteine in der Literatur beschrieben, die G4-Strukturen entwinden können. Jedoch konnten bisher nur wenige Proteine identifiziert werden, die in vivo die Faltung fördern oder G4-Strukturen stabilisieren.
Durch Yeast One-Hybrid (Y1H)-Screenings habe ich Zuo1 als neues G4 bindendes Protein identifiziert. In vitro Analysen bestätigten diese Interaktion und es stellte sich heraus, dass Zuo1 G4-Strukturen stabilisiert. Übereinstimmend mit den in vitro Daten konnte gezeigt werden, dass Zuo1 signifikant an G4-Motive im Genom von Saccharomyces ceresivisiae bindet. Genomweit überlappen G4-Motive, an die Zuo1 bindet, mit Stellen, an denen die DNA Replikation zum Stillstand kommt und vermehrt DNA Schäden vorkommen. Diese Ergebnisse legen nahe, dass Zuo1 eine Funktion während der DNA Reparatur oder in Zusammenhang mit dem Vorankommen der DNA Replikationsgabel hat, indem G4-Strukturen stabilisiert werden. Diese Hypothese wird außerdem durch genetische Experimente gestützt, wonach in Abwesenheit von Zuo1 die Genominstabilität zunimmt. Aufgrund dieser Daten war es möglich ein Model zu entwickeln, bei dem Zuo1 während der S-Phase G4-Strukturen bindet und stabilisiert wodurch die DNA Replikation blockiert wird. Diese Interaktion findet neben Stellen schadhafter DNA statt und unterstützt somit DNA Reparatur-Prozesse wie beispielsweise die Nukleotidexzisionsreparatur.
Als weiteres potentielles G4-bindendes Protein wurde Slx9 in Y1H-Screenings identifiziert. In vitro Experimente zeigten zwar, dass Slx9 mit höherer Affinität an G4-Strukturen bindet im Vergleich zu anderen getesteten DNA Konformationen, jedoch wurde in S. cerevisiae genomweit keine signifikante Bindung an G4-Motive festgestellt.
The formation of macromolecular complexes within the crowded environment of cells often requires aid from assembly chaperones. PRMT5 and SMN complexes mediate this task for the assembly of the common core of pre-mRNA processing small nuclear ribonucleoprotein particles (snRNPs). Core formation is initiated by the PRMT5-complex subunit pICln, which pre-arranges the core proteins into spatial positions occupied in the assembled snRNP. The SMN complex then accepts these pICln-bound proteins and unites them with small nuclear RNA (snRNA). Here, we have analyzed how newly synthesized snRNP proteins are channeled into the assembly pathway to evade mis-assembly. We show that they initially remain bound to the ribosome near the polypeptide exit tunnel and dissociate upon association with pICln. Coincident with its release activity, pICln ensures the formation of cognate heterooligomers and their chaperoned guidance into the assembly pathway. Our study identifies the ribosomal quality control hub as a site where chaperone-mediated assembly of macromolecular complexes can be initiated.
Biochemische und strukturelle Charakterisierung der Genexpressionsmaschinerie des Vaccinia Virus
(2018)
Die Familie der Pockenviren zeichnet sich durch ein komplexes DNA Genom aus und hat großes medizinisches Potential. Am eindrucksvollsten ist dies für das Vaccinia-Virus (VACV) belegt, welches nicht nur als Pocken-Impfstoff eingesetzt wird, sondern auch als onkolytisches Virus in der Tumorbiologie. VACV hat einen außergewöhnlichen Replikationszyklus, welcher ausschließlich im Zytoplasma der Wirtszelle stattfindet. Somit ist die gesamte virale Genexpressionsmaschinerie völlig unabhängig von kernvermittelten Reaktionen des Wirts und somit auch aus Sicht der Grundlagenforschung von größtem Interesse. Die Schlüsselkomponente der viralen Genexpression ist die makromolekulare DNA-abhängige RNA Polymerase (vvRPO), deren Untereinheiten allesamt Virus-kodiert sind. Zwar wurden in den letzten Jahren Protokolle zur biochemischen und funktionellen Charakterisierung der vvRPO etabliert, ein detailliertes Wissen über deren Zusammenlagerung in vivo und die räumlichen und zeitlichen Interaktionen mit den Transkriptions- bzw. Prozessierungsfaktoren sind aber weitgehend unbekannt.
Diese Arbeit umfasst Untersuchungen zur strukturellen und funktionellen Charakterisierung der vvRPO und seiner assoziierten Faktoren. Grundlage hierfür war die Etablierung eines Reinigungsprotokolls mithilfe eines neu konstruierten rekombinanten VACV (GLV-1h439). Diese Strategie erlaubte es hoch-molekulare native vvRPO Komplexe zu isolieren. Ein transkriptions-inaktiver Komplex (Komplex I) mit einer kalkulierten Masse von 575 kDa bestand aus den acht Untereinheiten des vvRPO Holoenzyms und den Polymerase-assoziierten Faktoren RAP94 und D6. Ein zweiter, transkriptionell aktiver Komplex (Komplex II) mit einer Masse von 803 kDa enthielt, neben dem Holoenzym der vvRPO, noch weitere Faktoren, die primär die Erkennung der DNA-Matrize und die Prozessierung der naszierenden RNA vermitteln. Hierbei handelt es sich um RAP94, das virale Capping Enzym bestehend aus den zwei Untereinheiten D1 und D12, A7 und dem Terminationsfaktor NPH I. Interessanterweise enthielt dieser Komplex zusätzlich mit E11 eine bislang unbekannte weitere Protein-Komponente, sowie tRNAGln und tRNAArg. Der isolierte Kompelx II ist daher ein Ribonukleoprotein (RNP).
Die Verfügbarkeit von hoch-reinen vvRPO Komplexen erlaubte es erstmals deren strukturelle Architektur zu untersuchen. Hierfür wurden drei experimentelle Ansätze, die klassische Röntgenstrukturanalyse, die Kryo-Elektronenmikroskopie (Kryo-EM) und Quervernetzungssstudien miteinander kombiniert. Die Strukturen der Komplexe I und II haben eine Auflösung von 11-12 Å, wobei auffällig war, dass beide eine markante strukturelle Ähnlichkeit zur eukaryotischen RNA Polymerase II aufwiesen. Darüber hinaus gelang es zusätzliche Bereiche im Komplex II zu definieren, welche die Polymerase-assoziierten Prozessierungsfaktoren beherbergen. Zudem konnte die atomare Struktur von E11, mittels Röntgenstrukturanalyse bei einer Auflösung von 1,9 Å, gelöst werden. Das E11 Protein besitzt ein neuartiges Faltungsmuster und weist einen intensiven Dimerisierungskontakt auf, welcher sich über vier ß-Faltblätter ausbildet.
Die im Rahmen dieser Arbeit erhaltenen Daten legen die Grundlage für ein detailliertes Verständnis der räumlichen Organisation der viralen Transkriptonsmaschinerie. Darüber hinaus werden sie funktionelle Studien ermöglichen, welche die Rolle der einzelnen Proteine, sowie der tRNAs bei der mRNA Synthese klären helfen.